首页> 美国卫生研究院文献>ISRN Oncology >Magnitude and Implications of Interfraction Variations in Organ Doses during High Dose Rate Brachytherapy of Cervix Cancer: A CT Based Planning Study
【2h】

Magnitude and Implications of Interfraction Variations in Organ Doses during High Dose Rate Brachytherapy of Cervix Cancer: A CT Based Planning Study

机译:高剂量率子宫颈癌近距离放射治疗期间器官剂量间变变化的幅度及其意义:基于CT的计划研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background. Quantifying the interfraction dose variations in the organs at risk (OAR) in HDR intracavitary brachytherapy (HDR ICBT). Methods. Rectum and bladder were contoured in 44 patients of cervical carcinoma on CT after each fraction of HDR ICBT (9 Gy/2 fractions). Interfraction dose variations (VARact) were calculated. Rigid image registration of consecutive fraction images allowed quantification of the hypothetical variation in dose (VARhypo) arising exclusively due to changes in applicator placement and geometry. VARhypo was regressed against the VARact to find out to what extent the applicator variation could explain the VARact in the OAR. The rest of the variation was assumed to be due to organ deformation. Results. The VARact in the dose to 2 cc of bladder and rectum were 1.46 and 1.16 Gy, respectively. Increased dose was seen in 16 and 23 patients in the subsequent fraction for bladder and rectum, respectively. Doses to OAR would have exceeded constraints in 16% patients if second fraction was not imaged. VARhypo explained 19% and 47% of the VARact observed for the bladder and rectum respectively. Conclusions. Significant interfraction variations in OAR doses can occur in HDR ICBT. Organ deformations are mostly responsible for this variation.
机译:背景。量化HDR腔内近距离放射治疗(HDR ICBT)中处于危险中的器官(OAR)的分数剂量变化。方法。在HDR ICBT的每一部分后(9 y Gy / 2部分),在CT上检查的44例宫颈癌患者的直肠和膀胱轮廓。计算了间次剂量变化(VARact)。连续分数图像的刚性图像配准允许量化仅由于施药器位置和几何形状的变化而引起的假设剂量变化(VARhypo)。将VARhypo与VARact进行回归分析,以了解施涂器的变化可以在多大程度上解释OAR中的VARact。其余的变化被认为是由于器官变形引起的。结果。膀胱和直肠对2 cc剂量的VARact分别为1.46和1.16 Gy。在随后的膀胱癌和直肠癌中,分别有16例和23例患者的剂量增加。如果未对第二部分成像,则OAR剂量将超过16%的患者限制。 VARhypo解释了分别在膀胱和直肠中观察到的VARact的19%和47%。结论。 HDR ICBT中OAR剂量的严重分数变化可能发生。器官变形是造成这种变化的主要原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号